Esperion publishes results of Phase 3 clinical trial on long-term safety of the new drug bempedoic acid

recently, Esperion(http://announced that it is developing the results of the long-termtrial(http:// for long-term safetythenew drug(http://) bempedoic acidAbout Bempedoic acid
Bempedoic acid is a daily oral ATP citric acid lysis (ACL) inhibitor used to lower LDL cholesterol (LDL-C) in patientsEsperion has submitted applications for new drugs to the u.SFDA(http://combination therapy for bempedoic acid and bempedoic acid/ezetimibe combination therapyBempedoic acid is a "first-in-class" oral ACL inhibitor that lowers theof the bio
synthetic (http:// of cholesterol, raising LDL receptor levels, causing more LDL-C to be removed from the blood cycle and lowering LDL-C levels in the blood Similar to the of the statin drug (http:// bempedoic acid can also reduce levels of hypersensitivity C-reactive protein (hsCRP), an inflammatory biomarker associated with cardiovascular disease 　For the Phase 3 clinical trial
a total of 2,230 patients with high LDL-C received a dose of 180 mg/day with a dose of bempedoic acid or placebo in this 52-week randomized double-blind, placebo-controlled global pipeline Phase 3 clinical trial These patients had LDL-C levels of at least 70 mg/dL, and their LDL-C levels could not be adequately controlled even with statins and other lipid control therapies, including the maximum tolerable dose 　　The results showed that at 12 weeks, bempedoic acid was able to reduce LDL-C levelby by 18% and hsCRP level by 22% compared to the control group during the 52-week long-term safety test (http:// , bempedoic acid showed good safety and tolerance, with no higher side effects than placebos